Skip to main content
Illustration of SpaceOAR Hydrogel.

SpaceOAR™ Hydrogel

A little space makes a BIG difference

SpaceOAR Hydrogel illustration.

What is SpaceOAR Hydrogel?

SpaceOAR Hydrogel is a PEG-based hydrogel designed to temporarily create space between the prostate and rectum, and reduce the radiation dose delivered to the rectum during radiation therapy. It has been clinically shown to help minimize urinary, sexual and bowel side effects and help protect the quality of life for prostate cancer patients undergoing radiation therapy.1–3

How SpaceOAR Hydrogel works

SpaceOAR Hydrogel has been shown to help minimize the risk of bowel, urinary and sexual side effects.1–3

Fewer bowel complications

Shown reduction in bowel quality of life declines by 70% at median 3 years.¹

Fewer urinary complications

Shown to reduce the likelihood of urinary quality of life decline by more than 60% at 3 years.¹

Fewer sexual complications

SpaceOAR Hydrogel patients who had erections sufficient for intercourse at baseline were 67% more likely to retain sexual function at 3 years.²

Get in touch with our team

Whether you're looking to get started with SpaceOAR Hydrogel or have general questions about the product, procedure or clinical data, our team is here to help.

We created this space together

When you choose SpaceOAR Hydrogel for your prostate cancer patients, you’re not only getting a device with proven clinical outcomes — you’re choosing a world-class customer experience.

  • 2011
    • One of the first publications utilizing SpaceOAR Hydrogel4
  • 2015
    • Randomized control trial published3
    • SpaceOAR Hydrogel launches in US
  • 2017
    • 3-year clinical trial results published1
  • 2018
    • Category 1 CPT code goes into effect5
    • Boston Scientific acquires SpaceOAR Hydrogel
  • 2020
    • Next-generation SpaceOAR Vue Hydrogel launches in US
    • Nationwide Medicare coverage achieved5
    • Recommended as a pre-treatment option within the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).6
  • 2021
    • SpaceOAR Vue Hydrogel launches in the EU
  • 2022
    • Over 220,000 SpaceOAR Hydrogel patients to date and growing*5
    • 225+ SpaceOAR publications5
    • Purchased at 20 of the top 20 cancer centers in the US5

*Number of patients is based on units shipped and a BSC proprietary algorithm.

What Radiation Oncologists and Urologists are saying about SpaceOAR Hydrogel

For prostate cancer patients undergoing radiation therapy, maintaining quality of life may be just as important as treating the cancer.


SpaceOAR Hydrogel for prostate cancer

Dr. Marcio Fagundes, Radiation Oncologist, describes his experience using SpaceOAR Hydrogel including clinical considerations, impact on workflow and his approach with patients.

Late rectal toxicity and how SpaceOAR Hydrogel helps

Dr. Sean Collins, Radiation Oncologist, discusses how SpaceOAR Hydrogel can help reduce late rectal toxicity in patients following radiation therapy.

Get SpaceOAR Hydrogel

Become a certified applier

Sign up

Get exclusive updates and clinical data.


  1. Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017 Apr;97(5):976–85.
  2. Hamstra DA, Mariados N, Sylvester J, et al. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: secondary analysis of a phase 3 trial. Pract Radiat Oncol. 2018 Jan-Feb;8(1):e7–e15. 
  3. Mariados N, Sylvester J, Shah D, et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal  spacer application in men undergoing prostate image guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):971–7. 
  4. Pinkawa M, Corral NE, Caffaro M, et al. Application of a spacer gel to optimize three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol. 2011 Sep;100(3):436–41.
  5. Data on file with Boston Scientific.
  6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed July 18, 2022. To view the most recent and complete version of the guideline, go to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

SpaceOAR and SpaceOAR Vue Hydrogels are intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR and SpaceOAR Vue Hydrogels to reduce the radiation dose delivered to the anterior rectum.

SpaceOAR and SpaceOAR Vue Hydrogels contain polyethylene glycol (PEG). SpaceOAR Vue Hydrogel contains iodine.

Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.

As with any medical treatment, there are some risks involved with the use of SpaceOAR and SpaceOAR Vue Hydrogels. Potential complications associated with SpaceOAR and SpaceOAR Vue Hydrogels include, but are not limited to: pain associated with SpaceOAR and SpaceOAR Vue Hydrogels injection, pain or discomfort associated with SpaceOAR and SpaceOAR Vue Hydrogels, local inflammatory reactions, infection (including abscess), urinary retention, urgency, constipation (acute, chronic, or secondary to outlet perforation), rectal tenesmus/muscle spasm, mucosal damage, ulcers, fistula, perforation (including prostate, bladder, urethra, rectum), necrosis, allergic reaction (localized or more severe reaction, such as anaphylaxis), embolism (venous or arterial embolism is possible and may present outside of the pelvis, potentially impacting vital organs or extremities), syncope and bleeding. The occurrence of one or more of these complications may require treatment or surgical intervention. URO-989811-AB.

All images are the property of Boston Scientific. All trademarks are the property of their respective owners.